Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Total Current Liabilities (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Total Current Liabilities for 8 consecutive years, with $14.5 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 14.96% to $14.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.5 million through Dec 2025, down 14.96% year-over-year, with the annual reading at $14.5 million for FY2025, 14.96% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $14.5 million at Whitehawk Therapeutics, up from $9.8 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $26.4 million in Q4 2023, with the low at $2.1 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $14.5 million, with a median of $14.9 million recorded in 2021.
  • The sharpest move saw Total Current Liabilities surged 470.45% in 2022, then tumbled 60.46% in 2025.
  • Over 5 years, Total Current Liabilities stood at $15.3 million in 2021, then increased by 23.32% to $18.8 million in 2022, then soared by 40.14% to $26.4 million in 2023, then plummeted by 35.31% to $17.1 million in 2024, then dropped by 14.96% to $14.5 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $14.5 million, $9.8 million, and $8.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.